Role and molecular mechanism of PEX16 mediated lipid deposition in the podocyte apoptosis of diabetic nephropathy

Status

Recruiting

Phases

Early Phase 1

Study type

Observational

Source

ChiCTR

Registry ID

ChiCTR2400085031

Enrollment

Unknown

Registered

2024-05-30

Start date

2022-02-01

Completion date

Unknown

Last updated

2024-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Nephropathy

Interventions

Healthy controls:None

T2DM:None

DN:None

Eligibility

Sex/Gender

All

Age

25 Years to 75 Years

Inclusion criteria

Inclusion criteria: Healthy controls: Fasting blood glucose levels should be below 7.0 mmol/L, glycosylated hemoglobin levels should be below 6.2%, urinary protein should test negative, creatinine levels should be within normal range, and individuals should be matched in terms of gender and age with the T2DM group and DN group. T2DM: Inclusion criteria include: newly diagnosed T2DM patients without drug therapy; fasting blood glucose levels above 7.0 mmol/L; glycosylated hemoglobin levels above 7%; negative urinary protein; no abnormal creatinine or fundus examination results; normal or well-controlled blood pressure; and matching gender and age with the DN group. DN group: According to the expert consensus on the prevention and treatment of DN (2014 edition), individuals with urine microalbumin levels above 30 mg/L or a quantification of 24-hour urinary protein exceeding 0.5 g, along with diabetic retinopathy, well-controlled or without hypertension were included.

Exclusion criteria

Exclusion criteria: Patients aged below 25 years or above 75 years; patients with comorbidities associated with increased urinary protein excretion; patients receiving medications that impact urinary protein levels, such as ACE inhibitors or ARBs; patients with endocrine and metabolic disorders other than diabetes; patients who have experienced heart failure or stroke within the past three months; patients exhibiting alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels exceeding 2.5 times the upper limit of normal range; patients with a history of malignant neoplasms; patients diagnosed with refractory hypertension.

Design outcomes

Primary

Measure	Time frame
PEX16;GNPAT;	—

Secondary

Measure	Time frame
Adipophilin;PPARa;	—

Countries

China

Contacts

Public ContactXia Zhu

Xuzhou Medical University

zhuxia@xzhmu.edu.cn+86 187 9542 5656

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026